The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update
Abstract
Purpose: To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents. Method: An Update Committee (“Committee”) reviewed and analyzed data published since 2002 through July 2007. MEDLINE and the Cochrane Collaboration Library databases were searched. Recommendations: For patients with chemotherapy-associated anemia, the Committee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, or falls below, 10 g/dL, to increase Hb and decrease transfusions. ESA treatment continues to be recommended for patients with low-risk myelodysplasia for similar reasons. There is no evidence showing increased survival as a result of ESA treatment. Conclusive evidence is lacking that, absent clinical circumstances necessitating earlier treatment, initiating ESAs at Hb levels greater than 10 g/dL either spares more patients from transfusion or substantially improves their quality of life. Starting doses and dose modifications based on response or lack thereof should follow the package insert. Continuing ESAs beyond 6 to 8 weeks in the absence of response, assuming appropriate dose increase has been attempted in nonresponders as per US Food and Drug Administration–approved labeling, does not seem to be beneficial, and ESA therapy should be discontinued. The Committee recommends monitoring iron stores and supplementing iron intake for ESA-treated patients. ESAs should be used cautiously with chemotherapy, or in clinical states, associated with elevated risk for thromboembolic complications. The Committee also cautions against ESA use for patients with cancer who are not receiving chemotherapy, since recent trials report increased thromboembolic risks and decreased survival under these circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Self-citationVansteenkiste, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1211 · Cited by 477
Wright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.177 · Cited by 417
Self-citationAuerbach, M., Ballard, H., Trout, J. R., McIlwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L., & Rana, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.119 · Cited by 414
Henry, D. H., Dahl, N. V., Auerbach, M., Tchekmedyian, S., & Laufman, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-231 · Cited by 264
Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh235 · Cited by 246
Self-citationSeidenfeld, J., Piper, M., Flamm, C., Hasselblad, V., Armitage, J. O., Bennett, C. L., Gordon, M. S., Lichtin, A. E., Wade, J. L., Woolf, S., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1204 · Cited by 222
Self-citationHedenus, M., Birgegård, G., Näsman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Lärfars, G., & Österborg, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404562 · Cited by 198
yndromes, I. T. C. O. S. T. G. R. R. I. M. Y. S. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01085.x · Cited by 174
Wilson, J., Yao, G., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., Bayliss, S., Moss, P., Stanworth, S., & Hyde, C. (2007) · Health Technology Assessment · doi:10.3310/hta11130 · Cited by 173
Self-citationThalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., & Richardson, P. G. G. (2006) · JAMA · doi:10.1001/jama.296.21.2558-c · Cited by 149
Self-citationErythropoietin or Darbepoetin for patients with cancer
Bohlius, J., Wilson, J. S., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S. E., Brunskill, S. J., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub4 · Cited by 149
Self-citationThatcher, N. J., Campos, E. S. D., Bell, D., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690369 · Cited by 129
Cella, D. F., Herbst, R. S., Lynch, T. J., Prager, D., Belani, C. P., Schiller, J. H., Heyes, A., Ochs, J. S., Wolf, M. K., Kay, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.153 · Cited by 115
Self-citationRoss, S. D., Allen, I. E., Henry, D. H., Seaman, C., Sercus, B., & Goodnough, L. T. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.003 · Cited by 111
Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer
Khuri, F. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078101 · Cited by 99
Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer
Abels, R. I., Larholt, K. M., Krantz, K. D., & Bryant, E. C. (1991) · Stem Cells · doi:10.1002/stem.5530090714 · Cited by 93
Mallinson, T., Cella, D. F., Cashy, J., & Holzner, B. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.07.012 · Cited by 92
Self-citationfor the Aranesp® 990111 Study Group, Smith, R. E., Tchekmedyian, N. S., Chan, D., Meza, L., Northfelt, D., Patel, R., Austin, M., Colowick, A. B., Rossi, G., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600994 · Cited by 75
Quality‐of‐life and health benefits of early treatment of mild anemia
Straus, D. J., Testa, M. A., Sarokhan, B. J., Czuczman, M. S., Tulpule, A., Turner, R. R., & Riggs, S. A. (2006) · Cancer · doi:10.1002/cncr.22221 · Cited by 67
Pagel, J. M., Lin, Y., Hedin, N., Pantelias, A., Axworthy, D. B., Stone, D. M., Hamlin, D. K., Wilbur, D. S., & Press, O. W. (2006) · Blood · doi:10.1182/blood-2005-11-4327 · Cited by 51
Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer
Abels, R. I., Larholt, K. M., Krantz, K. D., & Bryant, E. C. (1996) · The Oncologist · doi:10.1634/theoncologist.1-3-140 · Cited by 44
Charu, V., Belani, C. P., Gill, A. N., Bhatt, M., Tomita, D. K., Rossi, G., & Ben-Jacob, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-727 · Cited by 33
Vecchio, M. D., Gattinoni, L., Lozza, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.059 · Cited by 17
Late phase II study of S-1 in patients with taxane resistant breast cancer
Hino, M., Saeki, T., Sato, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.745 · Cited by 10
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Self-citationBlood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer
Khorana, A. A., Francis, C. W., Blumberg, N., Culakova, E., Refaai, M. A., & Lyman, G. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2377 · Cited by 373
Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2201 · Cited by 303
Self-citationJädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Metadata
- Authors
- Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Rarick, M. U., Regan, D. H., & Lichtin, A. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 132-149
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159923585
- Cited by
- 327
- References
- 29
- FWCI
- 32.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.